hybrid refractive/extended depth-of-focus intraocular lens (Lucidis; Swiss Advanced Vision, SAV-IOL SA, Neuchâtel, Switzerland) in glaucoma patients and to compare the contrast sensitivity results as regards to method of glaucoma control. Methods This retrospective multicenter study included 28 patients with visually impairing cataract and controlled early to moderate primary open angle glaucoma who underwent phacoemulsification and Lucidis intraocular lens implantation during the period from June 2021 to July 2023. Medical records were reviewed for baseline characteristics, severity, adequacy and method of control of glaucoma, details of cataract surgery and postoperative findings. Clinical outcomes were analysed at 3 months postoperatively and included uncorrected and best corrected near, intermediate and distance visual acuities, manifest refraction, contrast sensitivity, and patient satisfaction (adapted from the Catquest-9SF questionnaire). Results 42 eyes of 28 patients were included, with a male to female ratio of 1:1.8. There was a highly significant improvement in postoperative uncorrected and best corrected near, intermediate, and distance visual acuities (p < 0.001). Mean postoperative contrast sensitivity was 1.56 ± 0.11 log and there was no significant difference between medically and surgically controlled glaucoma (P = 0.08). There was a highly significant correlation between preoperative mean deviation and postoperative contrast sensitivity (p < 0.001). 26 (92.9%) patients were very satisfied. One (2.4%) eye developed dysphotopsia and no serious complications occurred throughout the study. Conclusions Lucidis IOL is effective and safe in patients with cataract and early to moderate POAG requesting spectacle independence. Adequate glaucoma control, regardless the method of control, and better preoperative mean deviation ensure good clinical outcomes.